How I find healthy foods on a budget while living with MASH
Eating is one of my pleasures in life, especially when the food is good. However, my current diet is much healthier than it was when…
Fatty liver disease
Fatty liver disease linked to projected rise in liver cancer
The proportion of cases of hepatocellular carcinoma (HCC) attributable to fatty liver disease is set to rise in the next 25 years, with obesity…
I was terrified of forgetfulness and brain fog, so I took action
Last May, I turned 56. I feel OK about being in middle age, but I’ve long had fears about growing old. What I didn’t anticipate…
Study testing fatty liver disease MASH therapy almost fully enrolled
Enrollment is nearly complete in a Phase 2b clinical trial that’s testing Corcept Therapeutics‘ experimental oral therapy miricorilant in people with metabolic-associated steatohepatitis (MASH),…
Why it’s important to participate in medical studies about MASH
Before I learned I was pregnant, I used to participate in medical studies to earn a little extra money. Living in a city with two…
Hoth, VA partner on head-to-head study in fatty liver disease mice
Hoth Therapeutics will support a U.S. Department of Veterans Affairs (VA) study testing treatment with glial cell-derived neurotrophic factor (GDNF) against semaglutide in a…
The benefits of having a pet while living with liver disease
In my nearly century-old house, most of my floors are hardwood or tile. In 1929, brooms did the trick, but my two cats, though short-haired,…
Madrigal wins US patent for Rezdiffra dosing regimen in MASH
The U.S. Patent and Trademark Office (USPTO) is granting a patent for Rezdiffra (resmetirom) — Madrigal Pharmaceuticals’ approved therapy for metabolic dysfunction-associated steatohepatitis (MASH),…
How weight loss can benefit those of us with liver disease
This week, I was on the hunt for a party dress for my 14-year-old daughter, who was invited to her best friend’s birthday party. I’ve…
Preclinical safety data support ETX-312 for MASH human trials
E-therapeutics announced positive preclinical toxicology data on ETX-312, its therapy for people with metabolic dysfunction-associated steatohepatitis (MASH), a severe form of fatty liver…
Recent Posts
- A boys’ day out brings a welcome sense of normalcy
- Rezdiffra reduces liver scarring in high-risk MASH patients: Trial data
- Used in Alagille mice, ASO therapy found to improve liver function
- Gene-editing therapy PBGENE-HBV shows encouraging trial results
- Livdelzi maintains benefits for up to 3 years in PBC: Phase 3 data